Skip to Content
Merck
  • Asymptomatic elevation of liver enzymes due to levetiracetam: a case report.

Asymptomatic elevation of liver enzymes due to levetiracetam: a case report.

Drug metabolism and drug interactions (2013-02-20)
Nitin K Sethi, Prahlad K Sethi, Josh Torgovnick, Edward Arsura, Frances Cukierwar
ABSTRACT

Levetiracetam is a commonly used broad-spectrum anticonvulsant efficacious in both partial and generalized seizures. It has an extremely favorable side effect profile with few drug-drug interactions, low potential for hematological and hepatic toxicity, and thus has rapidly become the preferred drug in patients with traumatic brain injuries who need seizure prophylaxis. We report, here, a patient who was started on levetiracetam for seizure prophylaxis after developing large bifrontal-parietal traumatic subdural hematomas (SDH) following a fall from a horse necessitating bifrontal craniotomies for evacuation. The patient developed an asymptomatic elevation of the liver enzymes. The liver enzymes trended back to normal after levetiracetam was stopped, and topiramate was initiated in its place.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piracetam
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard